Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

by Xuemin Jiang, Russ Wada, Bill Poland, Huub Jan Kleijn, Bin Fan, Guowen Liu, Hua Liu, Stephanie Kapsalis, Hua Yang, Kha Le
Published 2021-05-01

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

by Chi‐Chung Li, Tiffini Voss, Ken Kowalski, Bei Yang, Huub Jan Kleijn, Christopher J. Jones, Rolien Bosch, David Michelson, Matthew DeAngelis, Yang Xu, Iris Xie, Prajakti A. Kothare
Published 2020-05-01

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

by David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith
Published 2020-11-01